CA
OPRX icon

CastleArk Alternatives’s OptimizeRx OPRX Stock Holding History

CastleArk Alternatives’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-158,722
Closed -$13.6M – 204
2021
Q3 		$13.6M Buy
+158,722
New +$9.96M 0.52% 45

Other funds holding OPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

CastleArk Alternatives's OPRX Position: Q4 2021 in Review

CastleArk Alternatives sold out of OptimizeRx (OPRX) in Q4 2021, closing a stake of 158,722 shares — an estimated $13.6M sold.

CastleArk Alternatives first reported a position in OPRX in Q3 2021 and held it in 1 quarter. The position peaked at $13.6M in Q3 2021. 180 funds tracked by Wall St. Rank hold OPRX as of Q4 2021.

  • CastleArk Alternatives reported no remaining OptimizeRx position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 158,722 OptimizeRx shares in Q4 2021, an estimated $13.6M.
  • CastleArk Alternatives first reported a position in OptimizeRx in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's OptimizeRx position peaked at $13.6M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.